NASDAQ:HEPA

Hepion Pharmaceuticals Q3 2026 Earnings Results & Report

Hepion Pharmaceuticals logo
$0.12 +0.01 (+13.64%)
As of 11/17/2026 02:29 PM Eastern

Hepion Pharmaceuticals beat analyst earnings expectations in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$0.06 versus the -$200.00 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call
7:00 AM ET

Hepion Pharmaceuticals EPS Results

Actual EPS
-$0.06
Consensus EPS
-$200.00
Beat/Miss
Beat by +$199.94
One Year Ago EPS
N/A

Hepion Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Hepion Pharmaceuticals Q3 2026 Earnings FAQ

Hepion Pharmaceuticals (NASDAQ:HEPA) reported earnings of -$0.06 per share for Q3 2026, beating the consensus estimate of -$200.00. The report was announced on Monday, November 16, 2026.

Hepion Pharmaceuticals Earnings Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
See More Hepion Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hepion Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hepion Pharmaceuticals and other key companies, straight to your email.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals (NASDAQ:HEPA) was a clinical-stage biopharmaceutical company focused on developing treatments for chronic liver diseases. Its research centered on rencofilstat, an investigational oral cyclophilin inhibitor studied for conditions including nonalcoholic steatohepatitis (NASH) and liver fibrosis.

The company was formerly known as ContraVir Pharmaceuticals and adopted the Hepion name in 2019. Its work included clinical development of rencofilstat; the candidate was investigational and had not been approved as a treatment.

View Hepion Pharmaceuticals Profile